US FDA extends review of Bayer's menopause relief drug – Reuters

1. US FDA extends review of Bayer’s menopause relief drug  Reuters
2. FDA delays decision date on Bayer’s hot flash treatment by up to three months  Endpoints News
3. FDA extends review period for Bayer’s elinzanetant for vasomotor symptoms  Contemporary OB/GYN
4. FDA delays approval decision for Bayer menopause therapy  BioPharma Dive
5. FDA needs more time to review Bayer’s hot flash drug  FirstWord Pharma

Continue Reading